Lamb Weston sells 7% more fries for 63% less profit as the glut it built comes due

---

There is a particular kind of earnings report that flatters the eye and punishes the reader who keeps going. Lamb Weston's third quarter of fiscal 2026, reported on April 1, 2026, is one of them. The headline you saw was engineered to comfort: net sales of $1,564.8 million, up roughly 3% year over year; volume up 7%; the company even raised the midpoint of its full-year net-sales outlook and trimmed expected capital spending. A frozen-potato giant, the story went, is winning back share and turning a corner.

Read down two lines and the corner becomes a cliff. The same quarter that delivered 7% volume growth delivered a 7% decline in price/mix, the two cancelling to leave constant-currency sales flat. GAAP net income fell 63%, from $146.0 million a year earlier to $54.0 million. Diluted earnings per share went from $1.03 to $0.39. Adjusted EBITDA dropped 27% to $271.7 million. Adjusted income from operations fell 38%. And buried in the international segment was a $32.5 million pre-tax charge for raw potatoes the company grew, paid for, and then could not turn into sellable product fast enough — a literal write-off of food.

That is the entire thesis in one quarter. Lamb Weston is not growing into strength. It is running its plants harder and cheaper to keep them full, and the market is paying it less per case for the privilege. The forensic question is not whether volume is up — it plainly is — but what that volume costs, who is buying it, and whether a business built on a multi-year capacity expansion can earn an acceptable return when the demand it expanded for never showed up. The numbers say no, and the people now sitting on the board appear to agree.

The denominator is doing the work

Start with the oldest trick in packaged food: let the volume line carry the narrative and hope nobody divides. Lamb Weston wants you to anchor on "+7% volume" and "+3% net sales." But net sales rose by only $44.3 million on the quarter, and a favorable foreign-currency swing of $47.4 million more than accounted for all of it. Strip the currency and net sales were essentially flat on a constant-currency basis. So the company sold 7% more product, by physical volume, and got back roughly the same dollars it got a year earlier in real terms.

Run that through to the only ratio that matters: revenue per unit of volume is falling fast. A 7% volume gain that produces flat constant-currency sales means price/mix is eating the entire increment, dollar for dollar. The company itself quantifies it — price/mix down 7% — and attributes it to "price and trade support for customers and a mix shift toward faster-growing chain customers and private-label." Translated out of investor-relations language: Lamb Weston is cutting prices, funding more promotional support, and selling a richer slice of its mix into the lowest-margin channels in the business. Every one of those moves wins a case of fries. Every one of them gives back margin.

This is the denominator illusion. Growth measured in pounds of potato looks robust; growth measured in dollars of profit per pound looks like surrender. When a company leans on the flattering numerator and lets you supply the denominator yourself, it is usually because the denominator is the part that hurts.

Cyclical pain priced — by the company — as a strategy

Management's framing is that volume is the leading indicator and price will follow once the industry digests its overcapacity. That is the cyclical-priced-as-secular argument run in reverse, and it deserves scrutiny. The honest version of Lamb Weston's situation is straightforwardly cyclical: an industry — Lamb Weston, McCain, Simplot, Agristar and others — collectively built too much french-fry capacity during the post-pandemic restaurant rebound, betting that out-of-home eating would keep climbing. It did not climb the way the capital plans assumed. Restaurant traffic softened as inflation squeezed consumers, who ate out less and traded down when they did. The result is a classic price-taker squeeze: too many plants, not enough fries demanded, and pricing power flowing to the buyer rather than the seller.

Lamb Weston is a price-taker in two directions at once. On the input side, it does not control the cost of potatoes, edible oils, energy, or labor — and the quarter's margin commentary cited higher manufacturing costs alongside the unfavorable pricing. On the output side, its largest customers are quick-service restaurant chains with enormous buying leverage; when those chains see their own traffic soften, they push back on price and demand trade support, exactly the dynamic Lamb Weston described. A business squeezed on both ends of the income statement at once is not executing a clever volume strategy. It is absorbing a cyclical downturn and calling the absorption a plan.

The danger for investors is mistaking the trough for a new operating model. If price/mix is down 7% because the industry is oversupplied, the cure is capacity coming offline and demand recovering — both of which are outside management's control and neither of which has a guaranteed date. Pricing the stock as though the company has found a durable share-gain engine, when what it has actually found is a way to keep plants busy at lower margins, is the error this report is designed to encourage.

A write-off you can hold in your hand

Most quality-of-earnings games are abstract — a reserve release here, a capitalized cost there. Lamb Weston's third quarter handed investors a rare physical one: $32.5 million of raw potatoes in the international segment, charged off because sales volumes in the EMEA region came in below what the company had planted and contracted for. This is not a paper adjustment. It is the company telling you, in cash terms, that it grew more potatoes than the market would buy.

That single line is the capacity-glut thesis made tangible. You do not write off raw material because demand is strong; you write it off because you built — and planted — for a level of consumption that did not arrive. And the EMEA shortfall is not an isolated weather event. It is the international expression of the same global oversupply that is compressing North American price/mix. A company confident in its demand forecast does not end a quarter with tens of millions of dollars of spoiling inventory it cannot place.

It also raises an uncomfortable quality-of-earnings question about how the rest of the inventory and capacity base is being valued. If the international segment misjudged demand badly enough to destroy $32.5 million of raw product in a single quarter, an investor is entitled to ask how aggressively the broader plant footprint — much of it recently built — is being depreciated against a demand curve that keeps coming in soft. The write-off is the part that hit the income statement this quarter. The question is what is still sitting on the balance sheet at values that assume a recovery.

Adjusted versus GAAP: the gap is the story

Lamb Weston, like most of packaged food, asks to be judged on adjusted EBITDA. Indulge it for a moment, then look at the distance between the two columns. Adjusted EBITDA fell 27% to $271.7 million. Adjusted income from operations fell 38%. GAAP net income fell 63% to $54.0 million. The further down the income statement you travel — from the adjusted, pre-interest, pre-tax, pre-charge measure toward the bottom line a shareholder actually owns — the worse the decline gets.

That widening gap is not noise; it is structure. A 27% adjusted-EBITDA decline becoming a 63% net-income decline tells you that the items management strips out — restructuring, the potato write-off, the costs of running underutilized plants — are large and recurring enough to dominate the real result. When a company is mid-glut, the "one-time" charges have a way of arriving every quarter, each individually defensible, collectively the actual operating reality. The honest summary of the quarter is the GAAP one: the company earned $54.0 million, less than two-fifths of what it earned a year ago, while selling 7% more product. The adjusted figure exists to make that sentence harder to say out loud.

When activists win the board, read it as a verdict

Forensic analysts watch governance the way doctors watch fever — not as the disease, but as a signal of where the body is fighting. At Lamb Weston, the fever is high. Activist Jana Partners, which built a stake alongside Continental Grain, pressed the company through 2024 and 2025 over precisely the charge this article makes: that management added too much capacity and failed to account for softening demand. In July 2025 the campaign succeeded. Lamb Weston expanded its board to 13 from 11, four of Jana's nominees joined, and former Nestlé USA chief executive Bradley Alford took the chairman's seat.

Boards do not hand activists the chair and a bloc of seats when the existing strategy is working. They do it when large, sophisticated holders have concluded that the incumbent plan destroyed value and that someone needs to force a course correction — cost cuts, capacity discipline, and an openness to exploring a sale that management did not volunteer. Jana has reportedly pushed the company to roughly double its cost-savings ambitions, and the program now targets at least $250 million in reductions by the end of fiscal 2028, a figure some investors still consider light relative to the problem.

The activist verdict matters to the thesis because it is independent corroboration from people who did the work, took the risk, and won the proxy argument. When a Continental Grain — a deeply knowledgeable agricultural operator — and a Jana Partners both look at this asset and conclude the answer is to cut harder and possibly sell, an outside investor should weight that more heavily than a flattering volume headline. The smart money in the room is not betting on a self-driven turnaround. It is betting on surgery.

The cost-cut crutch and the capex retreat

Two of the quarter's "good news" items deserve to be reframed. First, Lamb Weston cut its expected fiscal 2026 capital expenditures to roughly $400 million from about $500 million. The bull reads this as discipline and free-cash-flow support. The forensic reader reads it as confession: a company that spent the last several years building capacity into a demand forecast that did not materialize is now slamming the brakes on the very investment program that created the glut. Cutting capex by a fifth is prudent — and it is also an admission that the prior spending was, in hindsight, too aggressive for the demand that arrived.

Second, the cost-savings program. Management now expects to exceed its $250 million cost-reduction target by fiscal 2028 and leaned on "improved cost discipline" as a margin offset. Cost cuts are real money and worth applauding. But a cost program is a denominator fix, not a demand fix. It can defend margins for a while against falling price/mix; it cannot manufacture pricing power in an oversupplied market. The risk is that investors capitalize the savings as though they were a growth engine, when in fact they are a bridge the company is building over a revenue hole it did not dig deep enough to escape. When the headline good news is "we will spend less and cut more," the underlying message is that the top line cannot be relied upon to do the work.

The slow tide: GLP-1 and the fry

The longest-dated worry is also the hardest to disprove, which is exactly why it belongs in a careful thesis rather than a panicked one. GLP-1 weight-loss drugs change how people eat, and surveys already show users spending less at fast-food chains and cutting impulse grocery purchases — both core demand pools for Lamb Weston's fries. The french fry is close to the archetypal product a GLP-1 user buys less of: a high-calorie, low-protein, impulse-driven side dish at the restaurants and grocery aisles where these drugs are reshaping the basket.

Honesty requires sizing the near term correctly. Credible analysis, including from ING, estimates GLP-1 drugs will trim total food demand by only around 0.25% in 2026 — a rounding error against this year's results, and nowhere near large enough to explain a 7% price/mix decline that is overwhelmingly a capacity-and-traffic story. So GLP-1 is not the cause of the current pain, and anyone who claims it is should be discounted.

But the thesis is about asymmetry over time. As injectable adoption widens and cheaper oral formulations arrive, the structural headwind to exactly Lamb Weston's category grows — slowly, then perhaps not so slowly. For a company already fighting an industry glut and softening restaurant traffic, a secular drift away from the fry is the last thing the long-term demand curve needs. It does not have to be a 2026 problem to be a problem worth pricing into a multi-year investment. The risk is not that GLP-1 sinks the fry next year. It is that it caps the recovery the bull case requires several years out, just as the industry hopes to grow back into its capacity.

Customer concentration cuts both ways

Lamb Weston's fortunes are lashed to a handful of very large quick-service restaurant chains. In a boom, that concentration is a moat: long contracts, predictable volumes, the reference customer that wins the next bid. In a downturn, it is a vise. When the chains that dominate your order book see their own traffic soften — and U.S. restaurant traffic has been soft — they do exactly what Lamb Weston reported: push for price and demand more trade support. The company's own explanation for the 7% price/mix decline names the mechanism: a mix shift toward "faster-growing chain customers and private-label," the two channels with the most buying power and the least margin to give.

That is the moat-versus-loophole problem. The same large customers that make Lamb Weston a scaled, hard-to-displace supplier also make it a price-taker the moment their demand wobbles. Winning more of their volume in a soft market — the very share gains management is celebrating — can mean winning the right to supply more cases at worse economics. Volume up, price down, mix worse: that is not a moat compounding. That is a loophole in the moat, and the customers know exactly where it is.

What the bulls genuinely get right

A fair forensic case has to concede where the bull thesis has real teeth, and here it has several. The volume growth is genuine and it is not trivial — 7% in the quarter at constant currency, on top of strong figures in prior quarters, driven by real customer-contract wins, share gains, and strong North American retention. A company losing the demand war does not put up volume numbers like that. Lamb Weston is winning shelf and winning bids, and in a commodity-adjacent business, scale and share are worth something durable.

The cost program is real and may be conservative. Targeting more than $250 million in savings by fiscal 2028, with management now expecting to exceed it, is meaningful money against a roughly $6.5 billion revenue base, and there is genuine upside if the activists succeed in pushing it further. The capex discipline, however one frames its origins, does support free cash flow at a time when the stock is cheap and pays a dividend yielding well above the packaged-food average — the board declared a $0.38 quarterly dividend, a yield around 3.6% at recent prices. Income investors are being paid to wait.

The valuation itself is a bull argument. With the shares near six-year lows after a sharp one-year decline, a great deal of bad news is already in the price. The presence of Jana Partners and Continental Grain — and reported interest from other activists — means engaged, capable owners are actively pushing for value creation and have not ruled out a sale that could crystallize a premium. And the GLP-1 threat, correctly sized, is genuinely small in the near term; bulls are right that it is being used as a scary headline far in excess of its 2026 impact. If the industry glut clears faster than feared and restaurant traffic stabilizes, the same operating leverage that is hurting Lamb Weston on the way down works powerfully on the way up. None of that is fantasy. It is the real other side of the trade.

The kicker

The bull case and the bear case actually agree on the facts; they disagree only on what the facts mean. Both sides see 7% volume growth fully offset by 7% lower price/mix, a 63% drop in GAAP profit, a $32.5 million pile of unsold potatoes, and an activist in the chairman's seat. The bull calls it a cheap stock at a cyclical trough with engaged owners and a fat dividend. The bear calls it a capital-intensive price-taker running its plants flat-out to defend share in a glut it helped build, masking a margin collapse behind a volume headline, with a slow GLP-1 tide rising under a demand curve that already disappoints. The pivot point is whether the industry's overcapacity clears before the cost cuts run out of room and the secular fry-demand drift turns from a footnote into a trend. Until price/mix stops falling, every additional case of fries is a smaller, not larger, claim on the bottom line — and that is the one number the company would rather you not divide.

The factory is full, the fries are flying, and the profit per case keeps shrinking — a company can run its lines flat out straight into the ground, and a 7% volume gain that ships with flat constant-currency sales and a 63% profit collapse is not a recovery, it is the sound of an industry discounting its way through a glut it built with its own capital.